{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T03:45:11Z","timestamp":1772163911946,"version":"3.50.1"},"reference-count":30,"publisher":"BMJ","issue":"4","funder":[{"name":"Sciensano"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Sex Transm Infect"],"accepted":{"date-parts":[[2020,7,5]]},"published-print":{"date-parts":[[2021,6]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>\n                      The number of reported cases of multiresistant\n                      <jats:italic>Mycoplasma genitalium<\/jats:italic>\n                      (MG) is increasing globally. The aim of this study was to estimate the prevalence of macrolide and possible fluoroquinolone resistance-associated mutations (RAMs) of MG in Belgium.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      The study was performed retrospectively on two sets of MG-positive samples collected in Belgium between 2015 and 2018. The first set of samples originated from routine surveillance activities and the second set came from a cohort of men who have sex with men (MSM) using pre-exposure prophylaxis to prevent HIV transmission. Detection of RAMs to macrolides and fluoroquinolones was performed on all samples using DNA sequencing of the 23S ribosomal RNA gene, the\n                      <jats:italic>gyrA<\/jats:italic>\n                      gene and the\n                      <jats:italic>parC<\/jats:italic>\n                      gene.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Seventy-one per cent of the MG samples contained a mutation conferring resistance to macrolides or fluoroquinolones (ParC position 83\/87). RAMs were more frequently found among men compared with women for fluoroquinolones (23.9% vs 9.1%) and macrolides (78.4% vs 27.3%). Almost 90% of the MG infections among MSM possessed a RAM to macrolides (88.4%). In addition, 18.0% of the samples harboured both macrolides and fluoroquinolone RAMs; 3.0% in women and 24.2% in MSM. Being MSM was associated with macrolide RAMs (OR 15.3), fluoroquinolone RAMs (OR 3.8) and having a possible multiresistant MG infection (OR 7.2).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The study shows an alarmingly high prevalence of MG with RAMs to macrolides and fluoroquinolones in Belgium. These results highlight the need to improve antimicrobial stewardship in Belgium in order to avoid the emergence of untreatable MG.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/sextrans-2020-054511","type":"journal-article","created":{"date-parts":[[2020,8,7]],"date-time":"2020-08-07T17:35:52Z","timestamp":1596821752000},"page":"297-303","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":25,"title":["An alarming high prevalence of resistance-associated mutations to macrolides and fluoroquinolones in\n                    <i>Mycoplasma genitalium<\/i>\n                    in Belgium: results from samples collected between 2015 and 2018"],"prefix":"10.1136","volume":"97","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1804-252X","authenticated-orcid":false,"given":"Irith","family":"De Baetselier","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2557-8998","authenticated-orcid":false,"given":"Chris","family":"Kenyon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wim","family":"Vanden Berghe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hilde","family":"Smet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristien","family":"Wouters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dorien","family":"Van den Bossche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bea","family":"Vuylsteke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2235-6038","authenticated-orcid":false,"given":"Tania","family":"Crucitti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2020,8,7]]},"reference":[{"key":"2024092104001709000_97.4.297.1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(17)30364-X"},{"key":"2024092104001709000_97.4.297.2","doi-asserted-by":"publisher","DOI":"10.1136\/sextrans-2017-053384"},{"key":"2024092104001709000_97.4.297.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.medmal.2019.03.007"},{"key":"2024092104001709000_97.4.297.4","doi-asserted-by":"publisher","DOI":"10.3201\/eid2504.181258"},{"key":"2024092104001709000_97.4.297.5","doi-asserted-by":"publisher","DOI":"10.1136\/sextrans-2019-054124"},{"key":"2024092104001709000_97.4.297.6","doi-asserted-by":"publisher","DOI":"10.1136\/sextrans-2019-054335"},{"key":"2024092104001709000_97.4.297.7","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1111\/jdv.13849","article-title":"European guideline on Mycoplasma genitalium infections","volume":"2016","author":"Jensen","year":"2016","journal-title":"J Eur Acad Dermatology Venereol"},{"key":"2024092104001709000_97.4.297.8","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1177\/0956462419890737","article-title":"Mycoplasma genitalium and antimicrobial resistance in Europe: a comprehensive review","volume":"31","author":"Fern\u00e1ndez-Huerta","year":"2020","journal-title":"Int J STD AIDS"},{"key":"2024092104001709000_97.4.297.9","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1097\/QAI.0000000000001791","article-title":"Choosing between daily and Event-Driven pre-exposure prophylaxis: results of a Belgian PreP demonstration project","volume":"79","author":"Reyniers","year":"2018","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2024092104001709000_97.4.297.10","doi-asserted-by":"crossref","DOI":"10.2196\/resprot.6767","article-title":"Pre-Exposure prophylaxis (PreP) as an additional tool for HIV prevention among men who have sex with men in Belgium: the Be-PrEP-ared study protocol","volume":"6","author":"De Baetselier","year":"2017","journal-title":"JMIR Res Protoc"},{"key":"2024092104001709000_97.4.297.11","doi-asserted-by":"crossref","DOI":"10.1002\/jia2.25407","article-title":"Daily and event-driven pre-exposure prophylaxis for men who have sex with men in Belgium: results of a prospective cohort measuring adherence, sexual behaviour and STI incidence","volume":"22","author":"Vuylsteke","year":"2019","journal-title":"J Int AIDS Soc"},{"key":"2024092104001709000_97.4.297.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.mimet.2011.12.017"},{"key":"2024092104001709000_97.4.297.13","doi-asserted-by":"crossref","unstructured":"Jensen JS . Protocol for the detection of Mycoplasma genitalium by PCR from clinical specimens and subsequent detection of macrolide resistance-mediating mutations in region V of the 23S rRNA gene. Totowa, NJ: Humana Press, 2012: 129\u201339.","DOI":"10.1007\/978-1-61779-937-2_8"},{"key":"2024092104001709000_97.4.297.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2010.05.011"},{"key":"2024092104001709000_97.4.297.15","first-page":"30154","article-title":"Prevalence of mutations associated with resistance to macrolides and fluoroquinolones in Mycoplasma genitalium: a systematic review and meta-analysis","volume":"S1473-3099","author":"Machalek","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"2024092104001709000_97.4.297.16","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.jgar.2017.09.018","article-title":"Macrolide resistance in Mycoplasma genitalium from female sex workers in Belgium","volume":"12","author":"Coorevits","year":"2018","journal-title":"J Glob Antimicrob Resist"},{"key":"2024092104001709000_97.4.297.17","unstructured":"Antimicrobial consumption - Annual Epidemiological Report for 2018. Available: https:\/\/www.ecdc.europa.eu\/en\/publications-data\/surveillance-antimicrobial-consumption-europe-2018 [Accessed 28 Feb 2020]."},{"key":"2024092104001709000_97.4.297.18","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/QAD.0000000000002020","article-title":"We need to consider collateral damage to resistomes when we decide how frequently to screen for chlamydia\/gonorrhoea in preexposure prophylaxis cohorts","volume":"33","author":"Kenyon","year":"2019","journal-title":"AIDS"},{"key":"2024092104001709000_97.4.297.19","first-page":"333","article-title":"European guideline on the management of Chlamydia trachomatis infections","volume":"2016","author":"Lanjouw","year":"2015","journal-title":"Int J STD AIDS"},{"key":"2024092104001709000_97.4.297.20","unstructured":"World Health Organization . Who guidelines for the treatment of Chlamydia trachomatis."},{"key":"2024092104001709000_97.4.297.21","doi-asserted-by":"publisher","DOI":"10.1136\/sextrans-2020-054425"},{"key":"2024092104001709000_97.4.297.22","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(18)30080-X"},{"key":"2024092104001709000_97.4.297.23","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1093\/cid\/ciy477","article-title":"Outcomes of resistance-guided sequential treatment of Mycoplasma genitalium infections: a prospective evaluation","volume":"68","author":"Read","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2024092104001709000_97.4.297.24","doi-asserted-by":"publisher","DOI":"10.1097\/OLQ.0000000000001009"},{"key":"2024092104001709000_97.4.297.25","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.00886-19","article-title":"Multicenter clinical evaluation of a novel multiplex real-time PCR (qPCR) assay for detection of fluoroquinolone resistance in Mycoplasma genitalium","volume":"57","author":"Fern\u00e1ndez-Huerta","year":"2019","journal-title":"J Clin Microbiol"},{"key":"2024092104001709000_97.4.297.26","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-019-3797-6"},{"key":"2024092104001709000_97.4.297.27","doi-asserted-by":"publisher","DOI":"10.1177\/0956462418820745"},{"key":"2024092104001709000_97.4.297.28","doi-asserted-by":"publisher","DOI":"10.3201\/eid2106.142013"},{"key":"2024092104001709000_97.4.297.29","doi-asserted-by":"publisher","DOI":"10.3201\/eid2305.161745"},{"key":"2024092104001709000_97.4.297.30","doi-asserted-by":"publisher","DOI":"10.1097\/OLQ.0000000000001095"}],"container-title":["Sexually Transmitted Infections"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/sextrans-2020-054511","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,21]],"date-time":"2024-09-21T07:01:43Z","timestamp":1726902103000},"score":1,"resource":{"primary":{"URL":"https:\/\/sti.bmj.com\/lookup\/doi\/10.1136\/sextrans-2020-054511"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,7]]},"references-count":30,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,5,17]]},"published-print":{"date-parts":[[2021,6]]}},"alternative-id":["10.1136\/sextrans-2020-054511"],"URL":"https:\/\/doi.org\/10.1136\/sextrans-2020-054511","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.03.22.20040840","asserted-by":"object"}]},"ISSN":["1368-4973","1472-3263"],"issn-type":[{"value":"1368-4973","type":"print"},{"value":"1472-3263","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,7]]}}}